지질 나노입자 제조 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2031년)

Persistence Market Research has recently released a comprehensive report on the worldwide market for lipid nanoparticle manufacturing. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global lipid nanoparticle manufacturing market from 2024 to 2031.

Key Insights:

• Lipid Nanoparticle Manufacturing Market Size (2024E):US$893.3 Mn
• Projected Market Value (2031F): US$1.8 Bn
• Global Market Growth Rate (CAGR 2024 to 2031):10.4%

Lipid Nanoparticle Manufacturing Market - Report Scope:

Lipid nanoparticles are versatile drug delivery systems used extensively in pharmaceuticals and biotechnology for the targeted delivery of therapeutics, vaccines, and genes. This market caters to various applications, including mRNA vaccines, cancer therapies, and other advanced drug formulations. The growth of lipid nanoparticle manufacturing is driven by increased research and development activities, heightened demand for efficient drug delivery systems, and advancements in lipid formulation technologies, thereby enhancing the bioavailability and stability of therapeutic agents.

Market Growth Drivers:

The global lipid nanoparticle manufacturing market is propelled by several key factors, including the surge in demand for mRNA vaccines, particularly in the wake of the COVID-19 pandemic, which has underscored the efficacy of lipid nanoparticles in vaccine delivery. Additionally, the growing prevalence of chronic diseases and the need for novel therapeutic approaches foster increased investment in lipid nanoparticle technologies. The development of targeted drug delivery systems utilizing lipid nanoparticles enables improved treatment efficacy, reduced side effects, and enhanced patient compliance, further driving market expansion.

Market Restraints:

Despite promising growth prospects, the lipid nanoparticle manufacturing market faces challenges related to regulatory hurdles, high production costs, and scalability issues. Stringent regulatory requirements for lipid-based formulations can lead to prolonged approval timelines, affecting market entry for new products. Moreover, the complex manufacturing processes and the necessity for specialized equipment contribute to high production costs, posing challenges for market penetration, especially for small and medium enterprises. Addressing these regulatory and economic barriers requires collaboration between industry stakeholders and regulatory bodies to streamline approval processes and ensure product safety.

Market Opportunities:

The lipid nanoparticle manufacturing market presents significant growth opportunities driven by technological innovations and expanding applications across various therapeutic areas. The increasing focus on personalized medicine and the development of tailored lipid formulations are expected to create new avenues for market players. Moreover, the rising trend of combination therapies utilizing lipid nanoparticles for enhanced therapeutic outcomes broadens the market scope. Strategic investments in research and development, partnerships with pharmaceutical companies, and advancements in nanotechnology are essential to capitalize on emerging opportunities and sustain market leadership.

Key Questions Answered in the Report:

• What are the primary factors driving the growth of the lipid nanoparticle manufacturing market globally?
• Which applications and therapeutic areas are driving the adoption of lipid nanoparticles across different healthcare settings?
• How are technological advancements reshaping the competitive landscape of lipid nanoparticle manufacturing?
• Who are the key players contributing to the lipid nanoparticle manufacturing market, and what strategies are they employing to maintain market relevance?
• What are the emerging trends and future prospects in the global lipid nanoparticle manufacturing market?

Competitive Intelligence and Business Strategy:

Leading players in the global lipid nanoparticle manufacturing market, including Moderna, Inc., BioNTech SE, and C3S, focus on innovation, product differentiation, and strategic collaborations to gain a competitive edge. These companies invest significantly in R&D to develop advanced lipid formulations and manufacturing techniques that cater to diverse therapeutic needs. Collaborations with research institutions, pharmaceutical companies, and regulatory agencies facilitate market access and promote technology adoption. Furthermore, an emphasis on clinical trials, evidence-based research, and patient education enhances market growth and improves therapeutic outcomes in the rapidly evolving lipid nanoparticle landscape.

Key Companies Profiled:

• Moderna, Inc.
• BioNTech SE
• C3S
• Pfizer Inc.
• Dicerna Pharmaceuticals, Inc.
• Novavax, Inc.
• Translate Bio, Inc.
• Arcturus Therapeutics
• Lipid Therapeutics GmbH
• Dendritic NanoTechnologies

Lipid Nanoparticle Manufacturing Market Segmentation

By Type of LNP

• Solid Lipid Nanoparticles (SLNs)
• Nanostructured Lipid Carriers (NLCs)

By Therapeutic Area

• Infectious Diseases
• Rare Diseases
• Oncological Disorders
• Neurodegenerative Disorders

By End User

• Pharmaceutical and Biotechnology Companies
• Academic & Research Institutes

By Region

• North America
• Europe
• East Asia
• South Asia and Oceania
• Latin America
• Middle East and Africa

Table of Contents

1. Executive Summary

• 1.1. Global Lipid Nanoparticle Manufacturing Market Snapshot, 2024-2031
• 1.2. Market Opportunity Assessment, 2024-2031, US$ Mn
• 1.3. Key Market Trends
• 1.4. Future Market Projections
• 1.5. Premium Market Insights
• 1.6. Industry Developments and Key Market Events
• 1.7. PMR Analysis and Recommendations

2. Market Overview

• 2.1. Market Scope and Definition
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Opportunity
  • 2.2.4. Key Trends
• 2.3. Macro-Economic Factors
  • 2.3.1. Global Sectorial Outlook
  • 2.3.2. Global GDP Growth Outlook
  • 2.3.3. Global Healthcare Spending Outlook
• 2.4. COVID-19 Impact Analysis
• 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

• 3.1. Product Adoption Analysis
• 3.2. Technology Assessment
• 3.3. Regulatory Landscape
• 3.4. Supply Chain Analysis
• 3.5. Key Deals and Mergers
• 3.6. PESTLE Analysis
• 3.7. Porter's Five Force Analysis

4. Global Lipid Nanoparticle Manufacturing Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 4.1. Key Highlights
  • 4.1.1. Market Size (US$ Mn) and Y-o-Y Growth
  • 4.1.2. Absolute $ Opportunity
• 4.2. Market Size (US$ Mn) Analysis and Forecast
  • 4.2.1. Historical Market Size (US$ Mn) Analysis, 2019-2023
  • 4.2.2. Current Market Size (US$ Mn) Analysis and Forecast, 2024-2031
• 4.3. Global Lipid Nanoparticle Manufacturing Market Outlook: Type of LNP
  • 4.3.1. Introduction / Key Findings
  • 4.3.2. Historical Market Size (US$ Mn) Analysis, By Type of LNP, 2019-2023
  • 4.3.3. Current Market Size (US$ Mn) Analysis and Forecast, By Type of LNP, 2024-2031
    • 4.3.3.1. Solid Lipid Nanoparticles (SLNs)
    • 4.3.3.2. Nanostructured Lipid Carriers (NLCs)
• 4.4. Market Attractiveness Analysis: Type of LNP
• 4.5. Global Lipid Nanoparticle Manufacturing Market Outlook: Therapeutic Area
  • 4.5.1. Introduction / Key Findings
  • 4.5.2. Historical Market Size (US$ Mn) Analysis, By Therapeutic Area, 2019-2023
  • 4.5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Therapeutic Area, 2024-2031
    • 4.5.3.1. Infectious Diseases
    • 4.5.3.2. Rare Diseases
    • 4.5.3.3. Oncological Disorders
    • 4.5.3.4. Neurodegenerative Disorders
    • 4.5.3.5. Others
• 4.6. Market Attractiveness Analysis: Therapeutic Area
• 4.7. Global Lipid Nanoparticle Manufacturing Market Outlook: End User
  • 4.7.1. Introduction / Key Findings
  • 4.7.2. Historical Market Size (US$ Mn) Analysis, By End User, 2019-2023
  • 4.7.3. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2024-2031
    • 4.7.3.1. Pharmaceutical and Biotechnology Companies
    • 4.7.3.2. Academic & Research Institutes
    • 4.7.3.3. Others
• 4.8. Market Attractiveness Analysis: End User

5. Global Lipid Nanoparticle Manufacturing Market Outlook: Region

• 5.1. Key Highlights
• 5.2. Historical Market Size (US$ Mn) Analysis, By Region, 2019-2023
• 5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Region, 2024-2031
  • 5.3.1. North America
  • 5.3.2. Europe
  • 5.3.3. East Asia
  • 5.3.4. South Asia and Oceania
  • 5.3.5. Latin America
  • 5.3.6. Middle East & Africa
• 5.4. Market Attractiveness Analysis: Region

6. North America Lipid Nanoparticle Manufacturing Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 6.1. Key Highlights
• 6.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2023
  • 6.2.1. By Country
  • 6.2.2. By Type of LNP
  • 6.2.3. By Therapeutic Area
  • 6.2.4. By End User
• 6.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024-2031
  • 6.3.1. U.S.
  • 6.3.2. Canada
• 6.4. Current Market Size (US$ Mn) Analysis and Forecast, By Type of LNP, 2024-2031
  • 6.4.1. Solid Lipid Nanoparticles (SLNs)
  • 6.4.2. Nanostructured Lipid Carriers (NLCs)
• 6.5. Current Market Size (US$ Mn) Analysis and Forecast, By Therapeutic Area, 2024-2031
  • 6.5.1. Infectious Diseases
  • 6.5.2. Rare Diseases
  • 6.5.3. Oncological Disorders
  • 6.5.4. Neurodegenerative Disorders
  • 6.5.5. Others
• 6.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2024-2031
  • 6.6.1. Pharmaceutical and Biotechnology Companies
  • 6.6.2. Academic & Research Institutes
  • 6.6.3. Others
• 6.7. Market Attractiveness Analysis

7. Europe Lipid Nanoparticle Manufacturing Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 7.1. Key Highlights
• 7.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2023
  • 7.2.1. By Country
  • 7.2.2. By Type of LNP
  • 7.2.3. By Therapeutic Area
  • 7.2.4. By End User
• 7.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024-2031
  • 7.3.1. Germany
  • 7.3.2. France
  • 7.3.3. U.K.
  • 7.3.4. Italy
  • 7.3.5. Spain
  • 7.3.6. Russia
  • 7.3.7. Turkiye
  • 7.3.8. Rest of Europe
• 7.4. Current Market Size (US$ Mn) Analysis and Forecast, By Type of LNP, 2024-2031
  • 7.4.1. Solid Lipid Nanoparticles (SLNs)
  • 7.4.2. Nanostructured Lipid Carriers (NLCs)
• 7.5. Current Market Size (US$ Mn) Analysis and Forecast, By Therapeutic Area, 2024-2031
  • 7.5.1. Infectious Diseases
  • 7.5.2. Rare Diseases
  • 7.5.3. Oncological Disorders
  • 7.5.4. Neurodegenerative Disorders
  • 7.5.5. Others
• 7.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2024-2031
  • 7.6.1. Pharmaceutical and Biotechnology Companies
  • 7.6.2. Academic & Research Institutes
  • 7.6.3. Others
• 7.7. Market Attractiveness Analysis

8. East Asia Lipid Nanoparticle Manufacturing Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 8.1. Key Highlights
• 8.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2023
  • 8.2.1. By Country
  • 8.2.2. By Type of LNP
  • 8.2.3. By Therapeutic Area
  • 8.2.4. By End User
• 8.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024-2031
  • 8.3.1. China
  • 8.3.2. Japan
  • 8.3.3. South Korea
• 8.4. Current Market Size (US$ Mn) Analysis and Forecast, By Type of LNP, 2024-2031
  • 8.4.1. Solid Lipid Nanoparticles (SLNs)
  • 8.4.2. Nanostructured Lipid Carriers (NLCs)
• 8.5. Current Market Size (US$ Mn) Analysis and Forecast, By Therapeutic Area, 2024-2031
  • 8.5.1. Infectious Diseases
  • 8.5.2. Rare Diseases
  • 8.5.3. Oncological Disorders
  • 8.5.4. Neurodegenerative Disorders
  • 8.5.5. Others
• 8.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2024-2031
  • 8.6.1. Pharmaceutical and Biotechnology Companies
  • 8.6.2. Academic & Research Institutes
  • 8.6.3. Others
• 8.7. Market Attractiveness Analysis

9. South Asia & Oceania Lipid Nanoparticle Manufacturing Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 9.1. Key Highlights
• 9.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2023
  • 9.2.1. By Country
  • 9.2.2. By Type of LNP
  • 9.2.3. By Therapeutic Area
  • 9.2.4. By End User
• 9.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024-2031
  • 9.3.1. India
  • 9.3.2. Southeast Asia
  • 9.3.3. ANZ
  • 9.3.4. Rest of South Asia & Oceania
• 9.4. Current Market Size (US$ Mn) Analysis and Forecast, By Type of LNP, 2024-2031
  • 9.4.1. Solid Lipid Nanoparticles (SLNs)
  • 9.4.2. Nanostructured Lipid Carriers (NLCs)
• 9.5. Current Market Size (US$ Mn) Analysis and Forecast, By Therapeutic Area, 2024-2031
  • 9.5.1. Infectious Diseases
  • 9.5.2. Rare Diseases
  • 9.5.3. Oncological Disorders
  • 9.5.4. Neurodegenerative Disorders
  • 9.5.5. Others
• 9.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2024-2031
  • 9.6.1. Pharmaceutical and Biotechnology Companies
  • 9.6.2. Academic & Research Institutes
  • 9.6.3. Others
• 9.7. Market Attractiveness Analysis

10. Latin America Lipid Nanoparticle Manufacturing Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 10.1. Key Highlights
• 10.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2023
  • 10.2.1. By Country
  • 10.2.2. By Type of LNP
  • 10.2.3. By Therapeutic Area
  • 10.2.4. By End User
• 10.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024-2031
  • 10.3.1. Brazil
  • 10.3.2. Mexico
  • 10.3.3. Rest of Latin America
• 10.4. Current Market Size (US$ Mn) Analysis and Forecast, By Type of LNP, 2024-2031
  • 10.4.1. Solid Lipid Nanoparticles (SLNs)
  • 10.4.2. Nanostructured Lipid Carriers (NLCs)
• 10.5. Current Market Size (US$ Mn) Analysis and Forecast, By Therapeutic Area, 2024-2031
  • 10.5.1. Infectious Diseases
  • 10.5.2. Rare Diseases
  • 10.5.3. Oncological Disorders
  • 10.5.4. Neurodegenerative Disorders
  • 10.5.5. Others
• 10.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2024-2031
  • 10.6.1. Pharmaceutical and Biotechnology Companies
  • 10.6.2. Academic & Research Institutes
  • 10.6.3. Others
• 10.7. Market Attractiveness Analysis

11. Middle East & Africa Lipid Nanoparticle Manufacturing Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 11.1. Key Highlights
• 11.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2023
  • 11.2.1. By Country
  • 11.2.2. By Type of LNP
  • 11.2.3. By Therapeutic Area
  • 11.2.4. By End User
• 11.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024-2031
  • 11.3.1. GCC Countries
  • 11.3.2. Egypt
  • 11.3.3. South Africa
  • 11.3.4. Northern Africa
  • 11.3.5. Rest of Middle East & Africa
• 11.4. Current Market Size (US$ Mn) Analysis and Forecast, By Type of LNP, 2024-2031
  • 11.4.1. Solid Lipid Nanoparticles (SLNs)
  • 11.4.2. Nanostructured Lipid Carriers (NLCs)
• 11.5. Current Market Size (US$ Mn) Analysis and Forecast, By Therapeutic Area, 2024-2031
  • 11.5.1. Infectious Diseases
  • 11.5.2. Rare Diseases
  • 11.5.3. Oncological Disorders
  • 11.5.4. Neurodegenerative Disorders
  • 11.5.5. Others
• 11.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2024-2031
  • 11.6.1. Pharmaceutical and Biotechnology Companies
  • 11.6.2. Academic & Research Institutes
  • 11.6.3. Others
• 11.7. Market Attractiveness Analysis

12. Competition Landscape

• 12.1. Market Share Analysis, 2024
• 12.2. Market Structure
  • 12.2.1. Competition Intensity Mapping By Market
  • 12.2.2. Competition Dashboard
• 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
  • 12.3.1. Certest Biotec
    • 12.3.1.1. Overview
    • 12.3.1.2. Segments and Products
    • 12.3.1.3. Key Financials
    • 12.3.1.4. Market Developments
    • 12.3.1.5. Market Strategy
  • 12.3.2. Evonik
    • 12.3.2.1. Overview
    • 12.3.2.2. Segments and Products
    • 12.3.2.3. Key Financials
    • 12.3.2.4. Market Developments
    • 12.3.2.5. Market Strategy
  • 12.3.3. Ascendia Pharmaceuticals
    • 12.3.3.1. Overview
    • 12.3.3.2. Segments and Products
    • 12.3.3.3. Key Financials
    • 12.3.3.4. Market Developments
    • 12.3.3.5. Market Strategy
  • 12.3.4. Lonza
    • 12.3.4.1. Overview
    • 12.3.4.2. Segments and Products
    • 12.3.4.3. Key Financials
    • 12.3.4.4. Market Developments
    • 12.3.4.5. Market Strategy
  • 12.3.5. Exelead (Merck KGaA)
    • 12.3.5.1. Overview
    • 12.3.5.2. Segments and Products
    • 12.3.5.3. Key Financials
    • 12.3.5.4. Market Developments
    • 12.3.5.5. Market Strategy
  • 12.3.6. CordenPharma
    • 12.3.6.1. Overview
    • 12.3.6.2. Segments and Products
    • 12.3.6.3. Key Financials
    • 12.3.6.4. Market Developments
    • 12.3.6.5. Market Strategy
  • 12.3.7. Curia Global, Inc.
    • 12.3.7.1. Overview
    • 12.3.7.2. Segments and Products
    • 12.3.7.3. Key Financials
    • 12.3.7.4. Market Developments
    • 12.3.7.5. Market Strategy
  • 12.3.8. Creative Biostructure
    • 12.3.8.1. Overview
    • 12.3.8.2. Segments and Products
    • 12.3.8.3. Key Financials
    • 12.3.8.4. Market Developments
    • 12.3.8.5. Market Strategy
  • 12.3.9. CD Bioparticles
    • 12.3.9.1. Overview
    • 12.3.9.2. Segments and Products
    • 12.3.9.3. Key Financials
    • 12.3.9.4. Market Developments
    • 12.3.9.5. Market Strategy
  • 12.3.10. BOC Sciences
    • 12.3.10.1. Overview
    • 12.3.10.2. Segments and Products
    • 12.3.10.3. Key Financials
    • 12.3.10.4. Market Developments
    • 12.3.10.5. Market Strategy
  • 12.3.11. Acuitas Therapeutics
    • 12.3.11.1. Overview
    • 12.3.11.2. Segments and Products
    • 12.3.11.3. Key Financials
    • 12.3.11.4. Market Developments
    • 12.3.11.5. Market Strategy
  • 12.3.12. ABP Biosciences, LLC
    • 12.3.12.1. Overview
    • 12.3.12.2. Segments and Products
    • 12.3.12.3. Key Financials
    • 12.3.12.4. Market Developments
    • 12.3.12.5. Market Strategy
  • 12.3.13. Recipharm AB
    • 12.3.13.1. Overview
    • 12.3.13.2. Segments and Products
    • 12.3.13.3. Key Financials
    • 12.3.13.4. Market Developments
    • 12.3.13.5. Market Strategy

13. Appendix

• 13.1. Research Methodology
• 13.2. Research Assumptions
• 13.3. Acronyms and Abbreviations